Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  nilotinib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 46 for your search:
Start Over
Multicenter, Phase?, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
Phase: Phase IV
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 19 and over
Sponsor: Other
Protocol IDs: 2014-01-112, NCT02389920
Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAMN107AKR01T, NCT01400074
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2303E1, NCT00718263
Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CML V, 2010-024262-22, NCT01657604
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107AIC05, 2012-005124-15, NCT01743989
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Phase: Phase III
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107ARU02, NCT02115386
Phase 3b Study to Determine the Conversion Rate From MMR to Molecular Response = 4 Log (MR4) After Two Years
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107ADE18T, 2013-000077-68, NCT02174445
Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 64
Sponsor: Other
Protocol IDs: 2013.837, NCT02201459
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients =60 Years in Deep Molecular Response
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: Other
Protocol IDs: AOBSTMO-OPTKIMA-2014, NCT02326311
Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CAMN107YCA03T, NCT01222143
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0697, NCI-2013-00551, NCT01751425
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAMN107ACA06T, OZM-051, NCT01914484
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-0128, NCI-2015-00044, NCT02225574
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107YDE19, NCT02253277
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2005-0048, NCI-2012-01313, NCT00129740
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: CDR0000632225, AMC-UUCM-2008-0310, NOVARTIS-AMC-UUCM-2008-0310, 2008-0310, NCT00844298
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 091728, NCT01140568
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P081237, NCT01168050
A Study of Nilotinib in Growing Vestibular Schwannomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OZM-024, NCT01201538
A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICR-CTSU/2009/10020, 2009-012945-49, Oxfordshire C 09/H0606/103, CRUK/09/028, CTA 15983/0226/001, ISRCTN 39058880, NCT01395121
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 55 and over
Sponsor: Other
Protocol IDs: EWALL-PH-02, 2010-022855-46, NCT01528085
Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 to 69
Sponsor: NCI, Other
Protocol IDs: IRB00007195, 1R21CA159265-01, NCT01620216
Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CAMN107AKR07T, NCT01690065
Start Over